<DOC>
	<DOCNO>NCT02460991</DOCNO>
	<brief_summary>This prospective , multicenter study conduct 40 center United States Outside United States ( OUS ) . Participants study randomly assign receive either ONCO-DOX sorafenib treatment . This study evaluate study participant ' outcome ( medical condition ) treat ONCO-DOX compare treat sorafenib alone .</brief_summary>
	<brief_title>A Study ONCO-DOX Locally Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>This prospective , two-arm , stratified randomize ( 1:1 ) , open label , control , multicenter Phase III trial evaluate safety efficacy ONCOZENE™ Microspheres load doxorubicin ( ONCO-DOX ) comparison orally administer sorafenib patient unresectable , locally-advanced hepatocellular carcinoma ( HCC ) . Patients stratify ECOG Performance Status 0 versus 1 , portal vein invasion ( yes vs. ) , alpha feto protein &lt; 400 versus ≥400 . They randomize site within stratum . The study conduct 40 center United States , Europe &amp; Asia . Enrolled patient randomize equal allocation study site . Patients follow two year onset treatment . The study ass prospectively efficacy safety DEB-TACE ( ONCO-DOX ) patient unresectable , locally-advanced HCC . The primary objective study compare overall survival DEB-TACE ( ONCO-DOX ) sorafenib treatment group .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Written Informed Consent 2 . ≥18 year age 3 . Diagnosis HCC 4 . Locally advanced HCC 5 . Preserved liver function 6 . Eastern Cooperative Oncology Group 0 1 1 . Presence extrahepatic spread disease . 2 . Macrovascular invasion lobar portal vein branch main portal vein . 3 . Candidate surgical resection , transplantation , local ablation . 4 . Prior intraarterial embolization , chemotherapy systemic therapy HCC . 5 . Any contraindication TACE . 6 . Platelet count &lt; 50,000/mm3 international normalize ratio &gt; 1.5 . 7 . Previous treatment anthracycline antibiotic ( e.g . Doxorubicin ) sorafenib . 8 . Unstable coronary artery disease recent myocardial infarct ( i.e . within 1 year ) . 9 . Known ejection fraction &lt; 50 % . 10 . Current infection require antibiotic therapy . 11 . Suffering know bleed disorder . 12 . Renal insufficiency ( serum creatinine &gt; 2 mg/dL ) . 13 . Aspartate aminotransferase and/or alanine transaminase &gt; 5 time upper limit normal . 14 . Presence advance liver disease . 15 . Any contraindication doxorubicin administration : 16 . Any comorbid condition social situation , high likelihood cause poor compliance study protocol jeopardize patient 's safety . 17 . Patient another primary tumor , exception conventional basal cell carcinoma , superficial bladder cancer , melanoma situ , treated prostate cancer currently without biochemical radiographic evidence active disease 18 . Participation clinical trial investigational device drug within 4 week study entry . 19 . Pregnant breastfeeding patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>